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committee together, he made a point to 
tell me that he was wrong in his assess-
ment of the need for the Journal of the 
American Academy of Dermatology. I 
recount this story because it speaks of 
his essence, his character and integrity 
— a person willing to listen and, when 
appropriate, change his opinion.
I next had the opportunity to work 
with Irwin when he was appointed to 
the Council on Government Liaison 
(currently the Commission on Health 
Policy) of the American Academy of 
Dermatology. At that time the Academy 
was shifting its Washington presence 
from one of monitoring to a more pro-
active role in the socioeconomic arena. 
Irwin, whose background was in aca-
demic and research issues, studied the 
effect of government’s involvement in 
the practice of medicine and became 
one of the most knowledgeable mem-
bers of the Academy on diagnosis-relat-
ed groups, gatekeepers, and physician 
reimbursement. He led strategy ses-
sions on how to inform and influence 
legislators and regulators regarding 
dermatologists’ unique contributions 
to patient care. Irwin was so effective 
as a committee member that he was 
appointed chairman. During his career, 
Irwin served on 16 Academy commit-
tees, councils, and task forces with a 
topic range from education and evalu-
ation to research.
In addition to his work for the 
Academy, this “organization man” held 
leadership positions in the Society for 
Investigative Dermatology, the American 
Board of Dermatology, the Association of 
Professors of Dermatology, the American 
Dermatology Association, the American 
Medical Association House of Delegates, 
and numerous advisory boards — and, 
of course, his real job as professor 
and chairman of the Department of 
Dermatology at New York University 
School of Medicine.
When Irwin was elected to the 
Board of Directors of the Academy he 
was what every director of an associa-
tion hopes for in a newly elected board 
member — knowledgeable, hardwork-
ing, attentive, responsive, and articu-
late. He studied the issues, asked ques-
tions, formed opinions, participated in 
debates, and had a positive influence on 
outcomes. He was respected by his col-
leagues on the board and was elected 
by them to the Executive Committee.
John Grupenhoff, consultant to the 
American Academy of Dermatology 
and the Society for Investigative 
Dermatology, 1975–2003:
Dr Irwin Freedberg played a unique 
role in dermatology and its interface 
with federal government activities from 
the middle 1970s.
While involved in governmen-
tal issues for the American Academy 
of Dermatology (he chaired the 
Government Relations Committee from 
1980 to 1982), he also played leader-
ship roles in the Society for Investigative 
Dermatology and in National Institutes 
of Health activities. He was president 
of the SID from 1981 to 1982 and had 
served on its board of directors earlier. 
He had a particular interest in research 
funding and regulatory issues. He 
served on councils for several of the 
National Institutes of Health, includ-
ing the National Institute of Allergy and 
Infectious Diseases (1977–1980), the 
National Cancer Institute (1983–1985), 
and the National Institute of Arthritis, 
Diabetes, and Digestive and Kidney 
Diseases (1985–1986).
Dr Freedberg fully understood the 
issues surrounding the congressio-
nal activities in 1987 to establish a 
separate National Institute of Arthritis 
and Musculoskeletal Diseases, which 
included skin research though its 
name did not reflect it. He worked 
with Dr Peyton Weary and other der-
matologists across the country to con-
vince Congress to include “Skin” in 
the Institute’s new name.
I especially enjoyed discussing with 
Irwin the politics of research, the per-
sonalities of members of Congress, 
and how the process was moving 
along, as well as the advocacy efforts 
that were ongoing. As can be seen 
from the sample above, the inter-
twined nature of his experiences has 
been invaluable to dermatology.
My last opportunity to work with 
Dr Freedberg was the “Burden of Skin 
Diseases” workshop in 2002 at the 
National Institutes of Health, which he 
chaired. The purpose of the meeting was 
to support, in a report on a congressional 
bill, language calling for evaluation of the 
economic impact of skin diseases as well 
as the emotional burdens they impose 
on patients and their families. At the 
meeting, I observed with considerable 
interest Dr Freedberg’s encouragement 
of the patient interest groups to outline 
their concerns to make sure they were 
fully discussed.
As many leaders of patient groups 
know, I regard them as the best advo-
cates for skin disease research in the 
federal government, especially in 
Congress. Dr Freedberg was a major 
advocate of patient groups and helped 
cement their relationship with derma-
tology organizations.
In summary, Irwin Freedberg contrib-
uted great leadership to the specialty of 
dermatology and to the organizations of 
which he was a member.
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Irwin M. Freedberg, MD, had an extraor-
dinary career in academic medicine. 
Others have focused on Irwin’s many 
contributions to research, education, 
and our professional organizations. I 
would like to focus, however, on Irwin’s 
interactions with the pharmaceutical 
industry. The relationship of academia 
and pharma has been at times a dif-
ficult one. As in many other aspects of 
dermatology, Irwin led the way in seek-
ing solutions and common ground that 
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resulted in both groups being better off. 
My reflections have been formed by my 
15 years in academic medicine, includ-
ing six years as a faculty member of 
New York University’s Department of 
Dermatology, as well as my personal 
experience as a physician who currently 
works in the pharmaceutical industry. 
All of Irwin’s interactions with the 
pharmaceutical industry and dermatol-
ogy were characterized by an adher-
ence to the highest of ethical standards. 
He constantly forced himself, his depart-
ment, and our specialty to examine the 
underlying motivations that governed 
their relationships with industry. Irwin 
never shirked from questioning, in both 
public and private forums, the appropri-
ateness of industry grants, contributions, 
or programs. Although his credentials as 
an academic investigator offered signifi-
cant opportunities for him to personally 
profit from relationships with industry, 
to the best of my knowledge, his long 
career was characterized by limited 
consultation for industry. He kept indus-
try at arm’s length, concerned with not 
only the appearance but also the sub-
stance of the potential conflict of interest 
between academe and the pharmaceu-
tical industry. This behavior, however, is 
not what made Irwin unique, for many 
academicians have maintained a distant 
and oftentimes disdainful relationship 
with industry. Irwin challenged the para-
digms. He sought to promote dialogue 
about the appropriate boundaries for 
ongoing business relationships between 
physicians and those in the business of 
developing and selling drugs. This ongo-
ing debate, encouraged by Irwin and oth-
ers, has contributed to the development 
of guidelines by the Pharmaceutical 
Research and Manufacturers of America 
(PhRMA), the Department of Health 
and Human Services (DHHS) Office of 
the Inspector General (OIG), and the 
American Medical Association (AMA). 
Within the past 5 years, all three of these 
organizations have developed guide-
lines — for the pharmaceutical industry 
in the case of PhRMA and DHHS-OIG 
and for physicians in the case of AMA 
— outlining the appropriate ethical rela-
tionship between pharma and health-
care providers. 
In addition to his role in promoting 
dialogue on the relationship between 
industry and dermatology, Irwin also 
supported initiatives to bring new drugs 
to our patients and to do it in an ethical 
manner. He inherited an active clinical 
trials unit when he was recruited to New 
York University and fostered its develop-
ment. He clearly understood some of the 
opportunities and synergies to be gained 
by active participation of academic 
dermatology programs in the drug 
development process and was con-
cerned with the decline in academic 
dermatology clinical trials units as a 
result of increased external competition. 
Because of his strong ethical standards, 
the credibility and value of the clinical 
research that was conducted at New 
York University were well known in 
both the academic community and the 
pharmaceutical sector. 
Irwin also recognized that industry 
and academia could work together to 
bring new products to our patients. As 
chair of the Department of Dermatology 
at New York University (1981–2005), 
Irwin championed a research and devel-
opment collaboration between derma-
tologists at New York University and 
Pfizer. This relationship led to the for-
mation, in 1995, of Anaderm Research 
Corporation, a drug discovery company 
dedicated to the targeted development 
of novel compounds to enhance skin 
and hair appearance. Anaderm is now a 
subsidiary of Pfizer and has several com-
pounds in early clinical development.
Irwin Freedberg’s legacy to the phar-
maceutical sector has as its foundation 
a core belief in the integrity of both aca-
demic medicine and the industry. Irwin 
believed that by constantly questioning 
the motivation that underpins their rela-
tionship, we strengthen both. His legacy 
includes not only the compounds in the 
Anaderm development pipeline, but 
also the challenge for us all to continue 
to debate the ethics of those interac-
tions. Through such constant debate he 
believed that we could find ways for 
academic institutions to partner with 
pharmaceutical companies for new 
drug discovery and the betterment of the 
lives of our patients. It is up to all of us in 
industry and academia to insure that this 
legacy does not fade.
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“Your epidermis is showing!” As kids of 
a dermatologist, we were the earliest 
tellers in our second grade classes of 
that riotous (for the teller) and embar-
rassing (for the tellee — with awkward 
glances around) joke. The wonder of 
the joke lies in its longevity, as our 
own kids have used it again in early 
elementary school.
As a medical student who nearly 
died of hepatitis in 1954, my father was 
guided toward dermatology because 
it was a new and exciting field, which 
would be “less stressful” than internal 
medicine. Perhaps it was, but I doubt it. 
Irwin might have chosen to run a small 
bed and breakfast on Cape Cod, but 
if he had, it would have been the best 
B&B on the Cape, one of the top bed 
and breakfasts in New England, and 
nationally recognized.
While Irwin had plenty of work at 
work, he had plenty of fun at home. 
Sports, travel, music, and tinker-
ing were among his many hobbies. 
His roots in Boston were strong; his 
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